Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes
Thursday, October 20, 2016
8:00 AM–3:40 PM ET
Agenda and Speakers
The most important advances in HCV research and clinical care in the last year will be summarized and presented by leading experts in the field, in a 1-day CME course setting.
Assessment of Needs
The full-day advanced CME course will focus on hepatitis C virus (HCV) infection. Rapid advances in HCV disease management, with available treatments capable of curing HCV, will require the ongoing attention of practitioners involved in HCV medicine.
On completion of the workshop, participants will be able to:
- Choose an appropriate regimen for individual HCV-infected patients who are starting treatment or who are being retreated
- Describe the effect of HCV on the liver, recognize how to stage liver disease, and why it is important to accurately stage
- List the key drug-drug interactions in patients with HCV/HIV coinfection who are being treated for both viruses
- Describe the current data on available HCV treatments, the emergence of drug resistance, and investigational and other treatment regimens
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This full-day advanced CME course is designed for experienced HIV practitioners and those who treat or intend to treat hepatitis C.
This activity is also relevant for other practitioners including nurse practitioners and other nursing professionals, physician assistants, pharmacists, and others.
Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed a week after the course minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 6.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 6.25 hours (0.625 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-16-272-L02-P
This course is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.
Merck & Co, Inc
Gilead Sciences, Inc